Overview

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder

Status:
Completed

Trial end date:
2000-06-01

Target enrollment:

Participant gender:

Summary

OBJECTIVES: I. Evaluate the safety and efficacy of the alpha-2 adrenergic agonist guanfacine in children and adolescents with Tourette syndrome or other chronic tic disorder, and attention deficit hyperactivity disorder.

Phase:

Phase 3

Details

Lead Sponsor:

National Center for Research Resources (NCRR)

Collaborator:

Yale University

Treatments:

Guanfacine